生长抑素类似物介导靶向显像及治疗的研究现状和进展

高玉婷; 王自正

doi:10.3760/cma.j.issn.1673-4114.2009.06.003

高玉婷 , 王自正

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 6: (330-334)

引用本文:

Citation:

生长抑素类似物介导靶向显像及治疗的研究现状和进展

南京医科大学附属南京第一医院核医学科, 南京 210006
基金项目:
国家自然科学基金(30700186)

The development of somatostatin analogues mediated tumor targeting and therapy

Department of Nuclear Medicine, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China

摘要: 放射性核素标记生长抑素类似物对神经内分泌肿瘤进行靶向诊断和靶向治疗已得到临床广泛认可。大多数生长抑素类似物仅对生长抑素受体2具有较高的亲和力,限制了其在临床中的应用。新一代生长抑素类似物如:1,4,7,10-四氮杂环十二烷-N,N',N",N'"-四乙酸-1-萘丙氨酸-奥曲肽(DOTA-NOC)等,可与更多亚型的生长抑素受体结合且具有更高的亲和力,可由发射不同射线的多种核素标记,已引起广泛重视。该文在介绍常规生长抑素类似物的基础上,着重讨论新的生长抑素类似物、新的螯合剂、新的标记核素及其新的组合,展望生长抑素受体介导肿瘤显像及治疗的前景。
- 生长抑素,受体 /
- 肿瘤 /
- 放射性核素显像 /
- 放射疗法
Abstract: Radionuclide labelled somatostatin analogues have been widely used in the detection of neuro-endocrine tumors. Till now, most of somatostatin analogues only have high affinity to somatostatin receptor 2(SSTR2), further clinical applications was limitted. A new generation of somatostatin analogues such as 1,4,7,10-tetraazacyclodocecane-N,N',N",N'"-tetaraacetic acid-Nal3-octertide(DOTA-NOC) etc,binding to somatostatin receptors not only SSTR2 but other subtypes has been used mainly in preclinical study. In this review, we discussed these new somatostatin analogues, chelating agent, and their new labelled compounds, these new radionuclide labelled somatostatin analogues may hold great promise for the receptor-mediated tumor imaging and treatments.
- Somatostatin,receptor /
- Tumor /
- Radionuclide imaging /
- Radiotherapy
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Hubalewska-Daydejczyk A,Trofimiuk M,Sowa-Staszczak A,et al.Somatostatin receptors expression (SSTR1-SSTR5)in pheochromo-cytomas.Przegl Lek,2008,65(9):405-407.
[2]	Shen HC,Wang XW,Liu YG.A tumor growth inhibition of paclitaxel-octreotide conjugates on human non small cell lung cancer experiment with mice.Zhonghua Yi Xue Za Zhi,2008,88(35):2498-2503.
[3]	Acunzo J,Thirion S,Roche C,et al.Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.Cancer Res,2008,68(24):10163-10170.
[4]	Krantic S.Peptides as regulators of the immuse system:emphasis on somatostatin.Peptides,2000,21(12):1941-1946.
[5]	Kaszper E,Hanzély Z,Szende B,et al.Examination of somatostatin receptor expression in recurrent childhood medulloblastomas.Magy Onkol,2008,52(4):351-355.
[6]	Virgolini I,Traub T,Novotny C,et aL Experience with indium-111 and yttrium-90-labeled somatostatin analogs.Curr Pharm Des,2002,8(20):1781-1807.
[7]	Elgeti F,Amthauer H,Denecke T,et al.Incidental detection of breast cancer by ⁶⁸Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours.Nuklearmedizin,2008,47(6):261-265.
[8]	Kuan CT,Wikstrand CJ,Me Lendon RE,et al.Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.Hybridoma,2009,28(6):389-403.
[9]	Pisarek H,Stepień T,Kubiak R,et al.Somatostatin receptors inhuman adrenal gland tumors-immunohistochemical study.Folia Histochem Cytobiol,2008,46(3):345-351.
[10]	Thomson VS,Narayanan K,Singh JC.Contrast induced nephropathy in urology.Indian J Urol,2009,25(4):437-445.
[11]	Wild D,Schmitt JS,Cinj M,et al.DOTA-NOC,a high-affinity ligand of somatostatin receptor subtypes 2,3 and 5 for labelling with various radiometals.Eur J Nucl Med Mol Imaging,2003,30(10):1338-1347.
[12]	Shah T,Kulakiene I,Quigley AM,et al.The role of ^99mTc-depreotide in the management of neuroendocrine tumours.Nucl Medi Commun,2008,29(5):436-440.
[13]	Van Den Bossche B,Van Belle S,De Winter F,et al.Early prediction of endocrine therapy effect in advanced breast cancer patients using ^99mTc-depreotide scintigraphy.J Nucl Med,2006,47(1):6-13.
[14]	Blum J,Nandmaker H,Lister-James J,et al.A multicenter trial with a somatostatin analog 99Tcm depreotide in the evaluation of solitary pulmonary nodules.Chest,2000,117(5):1232-1237.
[15]	王峰,王自正,姚薇萱,等.⁹⁹Tc^m-sandostatin生长抑素受体显像用于诊断肺癌.中华核医学杂志,2004,24(2):104-106.
[16]	Schottelius M,Wester HJ,Heubi JC,et al.Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.Bioconjug Chem,2002,13(5):1021-1030.
[17]	Lebtahi R,Le Cloirec J,Houzard C,et al.Detection of neuroendocrine tumors:^99mTC-P829 scintigraphy compared with ¹¹¹In-pentetreotide scintigraphy.J Nucl Med,2002,43(7):889-895.
[18]	Wester HJ,Schottelius M,Scheidhauer K,et al.PET imaging of somatostatin receptors:design,synthesis and preclinical evaluation of a novel ¹⁸F-labelled,carbohydrated analogue of octreotide.Eur J Nucl Med Mol Imaging,2003,30(1):117-122.
[19]	Wester HJ,Schottelius M,Scheidhauer K,et al. Comparison of radioiodinated TOC,TOCA and Mtr-TOCA:the effect of carbohydration on the pharmacokinetics.Eur J Nucl Med Mol Imaging,2002,29(1):28-38.
[20]	Virgolini I,Britton K,Buscombe J,et al.¹¹¹In-and 99Y-DOTA-lanreotide:results and implications of the MAURITIUS trial.Semin Nucl Med,2002,32(2):148-155.
[21]	Wild D,Häcke HR,Waser B,et al.⁶⁸Ga-DOTANOC:a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.Eur J Nucl Med Mol Imaging,2005,32(6):724.
[22]	Maggio R,Aloisi G,Silvano E,et al.Heterodimerization of dopamine receptors:new insights into functional and therapeutic significance.Parkinsonism Relat Disord,2009,15(4):S2-S7.
[23]	Lee LT,Schally AV,Liebow C,et al.Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.Anticancer Res,2008,28(5A):2599-2605.
[24]	Barresi V,Alafaci C,Salpietro F,et al.Sstr2Aimmunohisto-chemical expression in human meningiomas:is there a correlation with the histological grade,proliferation or microvessel density?.Oncol Rep,2008,20(3):485-492.

[1]	张玉 , 杨梦蝶 , 余飞 . 靶向PD-1/PD-L1放射性核素分子探针及其在恶性肿瘤中的应用. 国际放射医学核医学杂志, 2022, 46(6): 374-379. doi: 10.3760/cma.j.cn121381-202107003-00188
[2]	王秀娟 , 李险峰 . 生长抑素受体肿瘤显像的临床应用及研究进展. 国际放射医学核医学杂志, 2006, 30(4): 217-219.
[3]	杨明福 , 李前伟 . 肿瘤血管内皮生长因子受体核素显像研究现状. 国际放射医学核医学杂志, 2010, 34(1): 19-22. doi: 10.3760/cma.j.issn.1673-4114.2010.01.005
[4]	夏伟 , 罗全勇 , 袁志斌 . PET-CT在肿瘤放射治疗中的应用. 国际放射医学核医学杂志, 2006, 30(6): 331-335.
[5]	路璐 , 樊赛军 . 自噬对肿瘤放射治疗疗效的影响. 国际放射医学核医学杂志, 2019, 43(1): 61-67. doi: 10.3760/cma.j.issn.1673-4114.2019.01.011
[6]	凌萍 , 张旭光 , 涂彧 . 纳米金在肿瘤显像与放射治疗中的应用. 国际放射医学核医学杂志, 2011, 35(1): 59-61. doi: 10.3760/cma.j.issn.1673-4114.2011.01.016
[7]	翟红彦 , 苏成海 . 基因治疗联合放射治疗恶性肿瘤的分子机制. 国际放射医学核医学杂志, 2009, 33(2): 113-116. doi: 10.3760/cma.j.issn.1673-4114.2009.02.015
[8]	赵艳芝 , 李进 , 王芹 , 穆传杰 . 恶性肿瘤基因治疗和放射治疗相互作用的机制及联合治疗展望. 国际放射医学核医学杂志, 2006, 30(4): 250-253.
[9]	张耀文 , 曹永珍 , 李进 , 王芹 . 基因治疗联合放射治疗恶性肿瘤. 国际放射医学核医学杂志, 2008, 32(4): 247-250.
[10]	章鹤 , 宋建元 , 曹建平 . 肿瘤放射增敏药物的研究进展. 国际放射医学核医学杂志, 2014, 38(6): 408-411. doi: 10.3760/cma.j.issn.1673-4114.2014.06.014

点击查看大图

计量

文章访问数: 1596
HTML全文浏览量: 213
PDF下载量: 3

生长抑素类似物介导靶向显像及治疗的研究现状和进展

南京医科大学附属南京第一医院核医学科, 南京 210006

收稿日期: 2009-06-02

基金项目: 国家自然科学基金(30700186)

关键词:

摘要: 放射性核素标记生长抑素类似物对神经内分泌肿瘤进行靶向诊断和靶向治疗已得到临床广泛认可。大多数生长抑素类似物仅对生长抑素受体2具有较高的亲和力,限制了其在临床中的应用。新一代生长抑素类似物如:1,4,7,10-四氮杂环十二烷-N,N',N",N'"-四乙酸-1-萘丙氨酸-奥曲肽(DOTA-NOC)等,可与更多亚型的生长抑素受体结合且具有更高的亲和力,可由发射不同射线的多种核素标记,已引起广泛重视。该文在介绍常规生长抑素类似物的基础上,着重讨论新的生长抑素类似物、新的螯合剂、新的标记核素及其新的组合,展望生长抑素受体介导肿瘤显像及治疗的前景。